India Should Play Up R&D Strengths But Build "China-Like" Infrastructure - BIO India Conference.
This article was originally published in The Pink Sheet Daily
Executive Summary
India has moved from being seen as a strategic "outsourcing" destination to a "partner of choice" for multi-nationals, one exec says, but says also that India needs a strong infrastructure such as seen in Shanghai.
You may also be interested in...
AstraZeneca India R&D Head Balganesh Tanjore On "Drug Hunting" In India To Be At Vanguard Of Innovation
Balganesh Tanjore heads AstraZeneca PLC's innovation efforts in India from the company's Bangalore-based R&D center. The senior scientist is known for his pioneering studies in the field of tuberculosis, having worked on several new compounds. Tanjore keeps a low profile but those in the field of medical research respect his contributions and appreciate his efforts in putting together a very robust innovative infrastructure in India. In a rare media intervew, Tanjore spoke to PharmAsia News' India bureau about "drug hunting" in India, including linking up with academic institutions for better solutions.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.